Markets:

Overview

News

Currencies

International

Treasuries

Psyence Group Inc (OP:PSYGF)

0.1270 UNCHANGED

Last Price Updated: 12:07 PM EST, Nov 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Psyence Group Inc

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

How To Finance A Psychedelics Business? Learn From These Four Companies ↗

April 04, 2023

Clearmind Medicine Announces Pricing of $3.5 Million Public Offering

Via Benzinga

Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More ↗

March 27, 2023

Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses

Via Benzinga

Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio ↗

March 21, 2023

Psyence Partners with iNGENū for Palliative Care Clinical Trial

Via Benzinga

Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce ↗

January 24, 2023

Health Canada Oks Clinical-Grade MDMA Export To UK Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its manufacturing partners received a Health Canada export permit for no less...

Via Benzinga

Psychedelics Travel: Clinical-Grade Magic Mushrooms Extract Exported From Southern Africa To UK ↗

January 20, 2023

Lifesciences psychedelics biotech Psyence Group Inc. (OTCQB: PSYGF) recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in...

Via Benzinga

6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements ↗

January 10, 2023

Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space.

Via Benzinga

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗

December 19, 2022

Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

Via Benzinga

Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials ↗

December 16, 2022

Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).

Via Benzinga

Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU ↗

December 15, 2022

Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal.

Via Benzinga

European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed ↗

October 11, 2022

UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used...

Via Benzinga

International Magic Mushrooms: Where Are They Produced And Where Are They Headed? ↗

September 29, 2022

Psyence Group Inc.

Via Benzinga

Psyched: Magic Mushrooms Vs. Psychotherapy, Psilocybin For Frontline Health Workers & Protecting Peyote ↗

September 26, 2022

As a wave of news about psychedelics research and successful applications sweeps across the country and abroad, Psyched is back to wrap up the exciting movement of this rapidly evolving sector.

Via Benzinga

Magic Mushrooms Vs. Psychotherapy For Incurable Cancer Diagnosis Moves Forward In UK Clinical Trials ↗

September 19, 2022

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc.

Via Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved ↗

April 25, 2022

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami...

Via Benzinga

Psyence, Filament Strike Magic Mushroom Product Licensing Agreement: What You Need To Know ↗

April 19, 2022

Psyence Group (OTCQB: PSYGF) and Filament Health Corp. (OTCQB: FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Psyence Group Inc (OP:PSYGF)

Headline News about Psyence Group Inc

Starting at $3.75/week.

Subscribe Today